Regencell Bioscience Holdings Limited
HealthcareNASDAQ:RGC · NASDAQ Capital Market
-$0.69 today
Vol 0.08M · Avg 0.13M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$8.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.02, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $392.7K -47.3% | $745.6K -3.1% | $769.7K +27.3% | $604.4K +2184.5% | $26.5K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$392.7K +47.3% | -$745.6K +3.1% | -$769.7K -27.3% | -$604.4K -2184.5% | -$26.5K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $948.3K -11.1% | $1.1M -32.6% | $1.6M -37.0% | $2.5M +473.1% | $438.3K | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $2.4M -17.0% | $2.9M -37.7% | $4.7M -8.1% | $5.1M +441.4% | $943.0K | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $3.4M -15.4% | $4.0M -36.4% | $6.3M -17.6% | $7.6M +451.5% | $1.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $392.7K -47.3% | $745.6K -3.1% | $769.7K +27.3% | $604.4K +2184.5% | $26.5K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$3.2M +11.8% | -$3.6M +31.6% | -$5.3M +24.3% | -$7.0M -415.9% | -$1.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$3.8M +20.4% | -$4.7M +24.5% | -$6.3M +17.6% | -$7.6M -451.5% | -$1.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $185.8K -50.3% | $373.5K +76.7% | $211.3K +810.4% | $23.2K -32.9% | $34.6K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$3.6M +17.9% | -$4.4M +28.0% | -$6.1M +20.2% | -$7.6M -463.9% | -$1.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$3.6M +16.7% | -$4.3M +26.7% | -$5.9M +20.9% | -$7.4M -451.2% | -$1.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +17.2% | -$0 +26.9% | -$0 +20.7% | -$0 -435.7% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +17.2% | -$0 +26.9% | -$0 +20.7% | -$0 -435.7% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $494.5M +0.0% | $494.5M +0.0% | $494.5M +0.0% | $494.5M +2.9% | $480.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $494.5M +0.0% | $494.5M +0.0% | $494.5M +0.0% | $494.5M +2.9% | $480.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Axsome Therapeutics, Inc.
NASDAQ:AXSM
$13.21B
Masimo Corporation
NASDAQ:MASI
$9.42B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
Cytokinetics, Incorporated
NASDAQ:CYTK
$8.70B
AptarGroup, Inc.
NYSE:ATR
$7.54B
Merus N.V.
MRUS
$6.83B
Grifols, S.A.
NASDAQ:GRFS
$6.50B
Abivax S.A.
NASDAQ:ABVX
$6.35B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.04B
Stevanato Group S.p.A.
NYSE:STVN
$4.66B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does RGC generate?
Regencell Bioscience Holdings Limited (RGC) reported $0.00 of revenue in fiscal 2025.
Is RGC profitable?
Regencell Bioscience Holdings Limited (RGC) reported -$3,584,213.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.